Adaptimmune Therapeutics Q3 EPS $(0.18) Misses $(0.15) Estimate, Sales $7.32M Miss $10.28M Estimate
Portfolio Pulse from Benzinga Newsdesk
Adaptimmune Therapeutics reported Q3 losses of $(0.18) per share, missing the analyst consensus estimate of $(0.15) by 20%. The company also reported quarterly sales of $7.32 million, missing the analyst consensus estimate of $10.28 million by 28.80%. Despite the misses, both figures represent an increase from the same period last year.
November 08, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Adaptimmune Therapeutics' Q3 earnings and sales missed analyst estimates, which could negatively impact the stock in the short term.
Adaptimmune Therapeutics reported lower than expected earnings and sales for Q3. This miss could lead to a decrease in investor confidence and a potential drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100